Minoxidil 2% for Eyebrow Enhancement

NCT ID: NCT01672307

Last Updated: 2013-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare minoxidil 2% versus placebo in enhancement of eyebrows.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypotrichosis of Eyebrows Thinning Eyebrows

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Minoxidil lotion 2%

Minoxidil lotion 2% is applied twice daily to one eyebrow.

Group Type EXPERIMENTAL

Minoxidil lotion 2%

Intervention Type DRUG

Minoxidil lotion 2% is applied twice daily to one eyebrow.

Placebo

Placebo is applied twice daily to the other eyebrow.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo is applied twice daily to the other eyebrow.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minoxidil lotion 2%

Minoxidil lotion 2% is applied twice daily to one eyebrow.

Intervention Type DRUG

Placebo

Placebo is applied twice daily to the other eyebrow.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female aged 18-40 years
* hypotrichosis of eyebrows
* healthy
* informed consent obtained

Exclusion Criteria

* no underlying diseases
* no alopecia areata or trichotillomania
* no thyroid diseases
* no pregnancy or breast feeding
* no previous eyebrow tattoo, trauma or accident.
* no history of eyebrow or hair medications in 6 months
* no history of minoxidil or its ingredient allergy
* no history of eyebrow surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mae Fah Luang University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chuchai TANGLERTSAMPAN, MD

Instructor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chuchai Tanglertsampan, MD

Role: PRINCIPAL_INVESTIGATOR

MFL University Hospital (Bangkok)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MFL University Hospital (Bangkok)

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MFL University

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.